Clarifying the best TPO-RA schedule in MDS will be of great value, since 50% of these patients suffer from thrombocytopenia (59), which may be worsened by MDS therapy, and is mainly managed with transfusions and steroids. This evidence concerns the gene TPO and myelodysplastic syndrome.